Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Maria Gavriatopoulou and Meletios Dimopoulos.
Maria Gavriatopoulou
Connection Strength
14.969
Meletios Dimopoulos
  1. Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine. Clin Exp Med. 2021 Jul 20.
    View in: PubMed
    Score: 0.957
  2. SARS-CoV-2 Vaccines in Patients With Multiple Myeloma. Hemasphere. 2021 Mar; 5(3):e547.
    View in: PubMed
    Score: 0.930
  3. Emerging treatment strategies for COVID-19 infection. Clin Exp Med. 2021 May; 21(2):167-179.
    View in: PubMed
    Score: 0.911
  4. Organ-specific manifestations of COVID-19 infection. Clin Exp Med. 2020 Nov; 20(4):493-506.
    View in: PubMed
    Score: 0.894
  5. Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients. Leuk Lymphoma. 2019 03; 60(3):619-628.
    View in: PubMed
    Score: 0.804
  6. The extended 4-year follow-up results of the ELOQUENT-2 trial. Oncotarget. 2019 Jan 04; 10(2):82-83.
    View in: PubMed
    Score: 0.803
  7. How I treat rituximab refractory patients with WM. Oncotarget. 2018 Dec 07; 9(96):36824-36825.
    View in: PubMed
    Score: 0.798
  8. IMiDs for myeloma induced renal impairment. Oncotarget. 2018 Oct 26; 9(84):35476-35477.
    View in: PubMed
    Score: 0.792
  9. The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. Blood. 2018 01 25; 131(4):464-467.
    View in: PubMed
    Score: 0.743
  10. Efficacy and safety of elotuzumab for the treatment of multiple myeloma. Expert Opin Drug Saf. 2017 Feb; 16(2):237-245.
    View in: PubMed
    Score: 0.700
  11. Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia. Expert Opin Investig Drugs. 2017 Feb; 26(2):197-205.
    View in: PubMed
    Score: 0.699
  12. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer J. 2021 08 02; 11(8):138.
    View in: PubMed
    Score: 0.240
  13. Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. Cells. 2021 07 30; 10(8).
    View in: PubMed
    Score: 0.240
  14. Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis. Hemasphere. 2021 Aug; 5(8):e614.
    View in: PubMed
    Score: 0.239
  15. High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events. Vaccines (Basel). 2021 Jul 01; 9(7).
    View in: PubMed
    Score: 0.238
  16. Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. Blood. 2021 07 01; 137(26):3674-3676.
    View in: PubMed
    Score: 0.238
  17. Continuing Cancer Therapy through the Pandemic While Protecting Our Patients: Results of the Implementation of Preventive Strategies in a Referral Oncology Unit. Cancers (Basel). 2021 Feb 12; 13(4).
    View in: PubMed
    Score: 0.232
  18. COVID-19: time to flatten the infodemic curve. Clin Exp Med. 2021 May; 21(2):161-165.
    View in: PubMed
    Score: 0.231
  19. Response of an oncology unit in the midst of the COVID-19 outbreak. J Oncol Pharm Pract. 2020 Dec; 26(8):1947-1952.
    View in: PubMed
    Score: 0.227
  20. A revised international prognostic score system for Waldenström's macroglobulinemia. Leukemia. 2019 11; 33(11):2654-2661.
    View in: PubMed
    Score: 0.206
  21. Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome. Ann Hematol. 2019 Jun; 98(6):1427-1434.
    View in: PubMed
    Score: 0.203
  22. Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. Int J Cancer. 2019 07 15; 145(2):559-568.
    View in: PubMed
    Score: 0.201
  23. Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis. Amyloid. 2018 Dec; 25(4):234-241.
    View in: PubMed
    Score: 0.201
  24. Management of multiple myeloma bone disease: impact of treatment on renal function. Expert Rev Hematol. 2018 11; 11(11):881-888.
    View in: PubMed
    Score: 0.198
  25. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia. 2018 09; 32(9):1883-1898.
    View in: PubMed
    Score: 0.194
  26. Optimizing therapy in bortezomib-exposed patients with multiple myeloma. Expert Rev Hematol. 2018 06; 11(6):463-469.
    View in: PubMed
    Score: 0.192
  27. Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. Blood Cancer J. 2018 05 24; 8(5):46.
    View in: PubMed
    Score: 0.192
  28. Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma. Blood Cancer J. 2018 05 11; 8(5):42.
    View in: PubMed
    Score: 0.192
  29. Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. Blood Cancer J. 2018 03 09; 8(3):31.
    View in: PubMed
    Score: 0.190
  30. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J. 2018 01 12; 8(1):7.
    View in: PubMed
    Score: 0.188
  31. Rare manifestations of extramedullary myeloma: testicular plasmacytomas. Leuk Lymphoma. 2018 08; 59(8):2002-2004.
    View in: PubMed
    Score: 0.186
  32. Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases. Leuk Lymphoma. 2018 04; 59(4):983-987.
    View in: PubMed
    Score: 0.182
  33. Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy. Leuk Lymphoma. 2017 Oct; 58(10):2304-2309.
    View in: PubMed
    Score: 0.180
  34. Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy. Am J Hematol. 2017 Jul; 92(7):632-639.
    View in: PubMed
    Score: 0.179
  35. Cardiac and renal complications of carfilzomib in patients with multiple myeloma. Blood Adv. 2017 Feb 28; 1(7):449-454.
    View in: PubMed
    Score: 0.177
  36. Emerging treatment approaches for myeloma-related bone disease. Expert Rev Hematol. 2017 Mar; 10(3):217-228.
    View in: PubMed
    Score: 0.176
  37. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. Am J Hematol. 2015 Apr; 90(4):E60-5.
    View in: PubMed
    Score: 0.154
  38. Early and late endocrine complications of COVID-19. Endocr Connect. 2021 Sep 20; 10(9):R229-R239.
    View in: PubMed
    Score: 0.061
  39. Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review. J Infect. 2021 07; 83(1):1-16.
    View in: PubMed
    Score: 0.059
  40. Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection. Microorganisms. 2021 Mar 06; 9(3).
    View in: PubMed
    Score: 0.058
  41. Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection. Viruses. 2020 12 25; 13(1).
    View in: PubMed
    Score: 0.058
  42. Oncology during the COVID-19 pandemic: challenges, dilemmas and the psychosocial impact on cancer patients. Oncol Lett. 2020 Jul; 20(1):441-447.
    View in: PubMed
    Score: 0.055
  43. Reactive Vasodilation Predicts Mortality in Primary Systemic Light-Chain Amyloidosis. Circ Res. 2019 09 27; 125(8):744-758.
    View in: PubMed
    Score: 0.052
  44. Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. J Clin Oncol. 2019 06 01; 37(16):1403-1411.
    View in: PubMed
    Score: 0.051
  45. Meat, fish, dairy products and risk of hematological malignancies in adults - a systematic review and meta-analysis of prospective studies. Leuk Lymphoma. 2019 08; 60(8):1978-1990.
    View in: PubMed
    Score: 0.051
  46. Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study. Blood Cancer J. 2018 11 07; 8(11):102.
    View in: PubMed
    Score: 0.050
  47. Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2018 06; 18(6):431-437.
    View in: PubMed
    Score: 0.048
  48. Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. Blood. 2018 04 05; 131(14):1568-1575.
    View in: PubMed
    Score: 0.047
  49. Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma. Ann Hematol. 2017 Oct; 96(10):1707-1714.
    View in: PubMed
    Score: 0.045
  50. High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. Leuk Res. 2010 Mar; 34(3):399-402.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.